查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1985976

全球胜肽類治療藥物市場：市場規模、佔有率和趨勢分析（按類型、應用、製造商、給藥途徑、合成技術和地區分類），細分市場預測（2026-2033 年）

Peptide Therapeutics Market Size, Share & Trends Analysis Report By Type, By Application, By Type Of Manufacturers, By Route Of Administration, By Synthesis Technology, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肽類治療藥物市場概述

全球胜肽類藥物市場預計到 2025 年價值 1,408.6 億美元，預計到 2033 年將達到 2,945.8 億美元。

預計從 2026 年到 2033 年，該市場將以 8.73% 的複合年成長率成長。在關鍵疾病領域對標靶、高效治療方法的需求不斷成長的推動下，該市場正在穩步擴張。

代謝性疾病（尤其是糖尿病和肥胖症）的日益流行，持續推動已開發市場和新興市場對胜肽類藥物的巨大需求。 GLP-1受體促效劑的強勁商業性成功增強了人們對胜肽類藥物平台的信心，並加速了研發投入。製藥公司正優先推進胜肽類藥物創新，以期透過提高安全性、選擇性和耐受性來滿足尚未滿足的醫療需求。肽類藥物工程技術的進步，透過改善分子穩定性、受體特異性和半衰期，提升了整體治療效果。醫生對精準醫療的日益青睞，進一步加速了胜肽類藥物在臨床上的應用。生物製藥在整個醫療保健體系中日益普及，為胜肽類藥物的商業化創造了有利環境。這些因素共同促成了胜肽類藥物銷售的持續成長和市場的長期發展。

腫瘤學、胃腸道疾病、心血管疾病和罕見內分泌疾病等領域適應症的不斷擴大，進一步推動了胜肽類藥物的成長動能。胜肽受體標靶化策略正在提高癌症治療的精準度，並最大限度地降低全身性毒性。同時，長效製劑的持續創新正在減少給藥頻率，並提高慢性病患者的用藥依從性。口服胜肽類藥物遞送技術正透過吸收促進劑和製劑最佳化不斷進步，從而提高患者的用藥便利性，並擴大其適用人群。

各公司正投資研發具有雙重或多重受體活性的差異化候選藥物，以改善臨床療效。生技公司與大型製藥公司之間的策略合作正在加速研發進程並增強商業化能力。例如，2025年9月，GlobeNewswire報道了一項針對約6萬名66歲及以上美國聯邦醫療保險用戶的研究表明，與度SemaglutideDulaglutide肽可使主要心血管不利事件風險降低23%，死亡風險降低26%，心肌梗塞、中風、不穩定型心臟絞痛或心臟絞痛或心臟衰竭這些結果已在2025年歐洲糖尿病研究協會（EASD）年會上發表。

製造技術的進步正在提升整個胜肽價值鏈的可擴展性、一致性和成本效益。固相胜肽合成和混合生產技術的改進提高了產量、純度和批次間重現性，而合約研發生產機構（CDMO）產能的擴張則滿足了全球供應需求。例如，2025年5月，《製藥製造》雜誌報道稱，總部位於瑞士的巴赫姆公司正在擴大其在瑞士、美國和英國多個生產基地的產能，在布本多夫啟動了名為“K樓”的大型新工廠建設，將其位於加州維斯塔的工廠的年肽產能提高至約1噸，將其位於英國聖海倫斯的工廠的診斷肽產量翻番，並啟動了位於瑞士錫塞爾恩的新工廠的基礎設計工作，從而進一步加強了全球肽製造基礎設施。

目錄

第1章：分析方法和範圍

第2章執行摘要

第3章：胜肽類治療藥物市場：影響因素、趨勢與範圍

  • 母市場展望
  • 相關市場展望
  • 市場動態
  • 肽類治療藥物的分析工具
    • 波特五力分析
    • PESTEL 分析
  • 管道分析
    • 第一階段
    • 第二階段
    • 第三階段

第4章：胜肽類治療藥物市場：按類型分類的估算與趨勢分析

  • 肽類治療藥物市場：按類型分類的波動分析（2025-2033 年）
  • 創新的
  • 非專利的

第5章：胜肽類治療藥物市場：按應用分類的估算與趨勢分析

  • 肽類治療藥物市場：按應用領域分類的波動分析（2025-2033）
  • 代謝性疾病
  • 癌症
  • 神經系統疾病
  • 消化器官系統疾病
  • 心血管疾病
  • 疼痛
  • 感染疾病
  • 腎臟疾病
  • 皮膚病
  • 呼吸系統疾病
  • 其他

第6章：胜肽類治療藥物市場：按製造商類型分類的估算和趨勢分析

  • 肽類治療藥物市場：按生產商類型分類的波動分析（2025-2033 年）
  • 內部開發
  • 外包

第7章 胜肽類治療藥物市場：合成技術的估計與趨勢分析

  • 肽類治療藥物市場：依合成技術分類的波動分析（2025-2033）
  • 重組DNA技術
  • 固相胜肽合成（SPPS）
  • 混合
  • 液相肽合成（LPPS）
  • 其他

第8章：胜肽類治療藥物市場：依給藥途徑分類的估算與趨勢分析

  • 肽類治療藥物市場：按給藥途徑分類的波動分析（2025-2033 年）
  • 腸外給藥
  • 口服
  • 粘膜
  • 經肺途徑
  • 其他

第9章：胜肽類治療藥物市場：區域估算與趨勢分析

  • 肽類藥物各地區市場佔有率（2025-2033 年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭格局

  • 近期趨勢及影響分析：依主要市場參與企業
  • 公司分類
  • 主要企業概覽
  • 財務業績
  • 產品基準評效
  • 企業市場占有率分析（2025 年）
  • 公司簡介
    • Eli Lilly and Company
    • Pfizer Inc.
    • Amgen Inc.
    • Takeda Pharmaceutical Company Limited
    • AstraZeneca
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Novo Nordisk A/S
    • GSK plc
    • Ironwood Pharmaceuticals, Inc.
    • Radius Health, Inc.（Subsidiary of Gurnet Point Capital and Patient Square Capital）
    • Ipsen Pharma

第11章 結論

Product Code: 978-1-68038-179-5

Peptide Therapeutics Market Summary

The global peptide therapeutics market size was estimated at USD 140.86 billion in 2025 and is projected to reach USD 294.58 billion by 2033, growing at a CAGR of 8.73% from 2026 to 2033. The market is expanding steadily, supported by rising demand for targeted and high efficacy treatment options across major disease areas.

The increasing prevalence of metabolic disorders, particularly diabetes and obesity, continues to generate substantial demand for peptide-based drugs across developed and emerging markets. Strong commercial performance of GLP-1 receptor agonists has reinforced confidence in peptide platforms and accelerated research investments. Pharmaceutical companies are prioritizing peptide innovation to address unmet clinical needs with improved safety, selectivity, and tolerability profiles. Advances in peptide engineering have enhanced molecular stability, receptor specificity, and extended half-life, strengthening overall therapeutic performance. Growing physician preference for precision therapies is further elevating clinical adoption. Expanding biologics acceptance across healthcare systems is creating favorable conditions for peptide commercialization. These combined factors are contributing to sustained revenue expansion and long-term market growth.

Growth momentum is further supported by expanding applications in oncology, gastrointestinal disorders, cardiovascular conditions, and rare endocrine diseases. Peptide receptor targeting strategies are improving therapeutic precision and minimizing systemic toxicity in cancer treatment, while continuous innovation in long-acting formulations has reduced dosing frequency and improved patient adherence across chronic disease segments. Oral peptide delivery technologies are advancing through absorption enhancers and formulation optimization, increasing patient convenience and broadening eligible populations.

Companies are investing in differentiated pipeline candidates with dual or multi receptor activity to improve clinical outcomes, and strategic collaborations between biotechnology firms and major pharmaceutical companies are accelerating development timelines and strengthening commercialization capabilities. For instance, in September 2025, GlobeNewswire reported that once weekly injectable semaglutide was associated with a 23% reduced risk of major adverse cardiovascular events compared to dulaglutide in nearly 60,000 US Medicare patients aged 66 years or older, along with a 26% lower risk of death and a 25% lower risk of heart attack, stroke, hospitalization for unstable angina or heart failure and death from any cause, with results presented at the 2025 European Association for the Study of Diabetes Annual Meeting.

Manufacturing advancements are contributing to greater scalability, consistency, and cost efficiency across the peptide value chain. Improvements in solid phase peptide synthesis and hybrid production technologies are enhancing yield, purity, and batch reproducibility, while expanded capacity among contract development and manufacturing organizations is supporting global supply requirements. For instance, in May 2025, Pharma Manufacturing reported that Swiss based Bachem expanded multisite production capacities across Switzerland, the United States, and the United Kingdom, commenced construction of a new large scale facility known as Building K in Bubendorf, increased annual peptide production capacity at its Vista, California site to nearly one metric ton, doubled diagnostic peptide output at its St Helens site in the UK, and initiated concept design work for an additional facility in Sisseln, Switzerland, further strengthening global peptide manufacturing infrastructure.

Global Peptide Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global peptide therapeutics market report based on application, type, type of manufacturer, route of administration, synthesis technology, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Innovative
  • Generic
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Metabolic Disorders
  • Cancer
  • Neurological Disorders
  • Gastrointestinal Disorders
  • Cardiovascular Disorders
  • Pain
  • Infectious Disease
  • Renal Disorders
  • Dermatological Disorders
  • Respiratory Disorders
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Parenteral Route
  • Oral Route
  • Mucosal
  • Pulmonary
  • Others
  • Synthesis Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Recombinant DNA Technology
  • Solid-Phase Peptide Synthesis (SPPS)
  • Hybrid
  • Liquid-Phase Peptide Synthesis (LPPS)
  • Others
  • Type of Manufacturers Outlook (Revenue, USD Million, 2021 - 2033)
  • Inhouse
  • Outsourced
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Peptide Therapeutics Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Increasing prevalence of cancer
        • 3.3.1.1.1. Cancer incidence data
      • 3.3.1.2. Technological advancements
      • 3.3.1.3. Presence of strong product pipeline
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Increasing complexity of peptides
      • 3.3.2.2. High cost of manufacturing equipment
  • 3.4. Peptide Therapeutics Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
  • 3.5. Pipeline Analysis
    • 3.5.1. Phase 1
    • 3.5.2. Phase 2
    • 3.5.3. Phase 3

Chapter 4. Peptide Therapeutics Market: Type Estimates & Trend Analysis

  • 4.1. Peptide Therapeutics Market: Type Segment Dashboard
  • 4.2. Peptide Therapeutics Market: By Type Movement Analysis, 2025 & 2033 (USD Million)
  • 4.3. Innovative
    • 4.3.1. Innovative Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Generic
    • 4.4.1. Generic Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Peptide Therapeutics Market: By Application Estimates & Trend Analysis

  • 5.1. Peptide Therapeutics Market: Application Segment Dashboard
  • 5.2. Peptide Therapeutics Market: By Application Movement Analysis, 2025 & 2033 (USD Million)
  • 5.3. Metabolic Disorders
    • 5.3.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Neurological Disorders
    • 5.5.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Gastrointestinal Disorders
    • 5.6.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Cardiovascular Disorders
    • 5.7.1. Cardiovascular Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Pain
    • 5.8.1. Pain Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Infectious Disease
    • 5.9.1. Infectious Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.10. Renal Disorders
    • 5.10.1. Renal Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.11. Dermatological Disorders
    • 5.11.1. Dermatological Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.12. Respiratory Disorders
    • 5.12.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.13. Others
    • 5.13.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Peptide Therapeutics Market: Type of Manufacturer Estimates & Trend Analysis

  • 6.1. Peptide Therapeutics Market: Type of Manufacturer Segment Dashboard
  • 6.2. Peptide Therapeutics Market: By Type of Manufacturer Movement Analysis, 2025 & 2033 (USD Million)
  • 6.3. Inhouse
    • 6.3.1. Inhouse Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Outsourced
    • 6.4.1. Outsourced Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Peptide Therapeutics Market: Synthesis Technology Estimates & Trend Analysis

  • 7.1. Peptide Therapeutics Market: Synthesis Technology Segment Dashboard
  • 7.2. Peptide Therapeutics Market: Synthesis Technology Movement Analysis, 2025 & 2033 (USD Million)
  • 7.3. Recombinant DNA Technology
    • 7.3.1. Recombinant DNA Technology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Solid-Phase Peptide Synthesis (SPPS)
    • 7.4.1. Solid-Phase Peptide Synthesis (SPPS) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Hybrid
    • 7.5.1. Hybrid Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Liquid-Phase Peptide Synthesis (LPPS)
    • 7.6.1. Liquid-Phase Peptide Synthesis (LPPS) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Peptide Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Peptide Therapeutics Market: Route of Administration Segment Dashboard
  • 8.2. Peptide Therapeutics Market: Route of Administration Movement Analysis, 2025 & 2033 (USD Million)
  • 8.3. Parenteral Route
    • 8.3.1. Parenteral Route Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4. Oral Route
    • 8.4.1. Oral Route Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Mucosal
    • 8.5.1. Mucosal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Pulmonary
    • 8.6.1. Pulmonary Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Others
    • 8.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Peptide Therapeutics Market: Regional Estimates & Trend Analysis

  • 9.1. Peptide Therapeutics Market Share, By Region, 2025 & 2033 (USD Million)
  • 9.2. North America
    • 9.2.1. North America Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. Key Country Dynamics
      • 9.2.2.2. Target Disease Prevalence
      • 9.2.2.3. Regulatory Framework
      • 9.2.2.4. Reimbursement Framework
      • 9.2.2.5. U.S. Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Key Country Dynamics
      • 9.2.3.2. Target Disease Prevalence
      • 9.2.3.3. Regulatory Framework
      • 9.2.3.4. Reimbursement Framework
      • 9.2.3.5. Canada Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.2.4. Mexico
      • 9.2.4.1. Key Country Dynamics
      • 9.2.4.2. Target Disease Prevalence
      • 9.2.4.3. Regulatory Framework
      • 9.2.4.4. Reimbursement Framework
      • 9.2.4.5. Mexico Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Target Disease Prevalence
      • 9.3.2.3. Regulatory Framework
      • 9.3.2.4. Reimbursement Framework
      • 9.3.2.5. Uk Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Target Disease Prevalence
      • 9.3.3.3. Regulatory Framework
      • 9.3.3.4. Reimbursement Framework
      • 9.3.3.5. Germany Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Target Disease Prevalence
      • 9.3.4.3. Regulatory Framework
      • 9.3.4.4. Reimbursement Framework
      • 9.3.4.5. France Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Key Country Dynamics
      • 9.3.5.2. Target Disease Prevalence
      • 9.3.5.3. Regulatory Framework
      • 9.3.5.4. Reimbursement Framework
      • 9.3.5.5. Italy Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Key Country Dynamics
      • 9.3.6.2. Target Disease Prevalence
      • 9.3.6.3. Regulatory Framework
      • 9.3.6.4. Reimbursement Framework
      • 9.3.6.5. Spain Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Key Country Dynamics
      • 9.3.7.2. Target Disease Prevalence
      • 9.3.7.3. Regulatory Framework
      • 9.3.7.4. Reimbursement Framework
      • 9.3.7.5. Denmark Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Key Country Dynamics
      • 9.3.8.2. Target Disease Prevalence
      • 9.3.8.3. Regulatory Framework
      • 9.3.8.4. Reimbursement Framework
      • 9.3.8.5. Sweden Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Key Country Dynamics
      • 9.3.9.2. Target Disease Prevalence
      • 9.3.9.3. Regulatory Framework
      • 9.3.9.4. Reimbursement Framework
      • 9.3.9.5. Norway Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.2. Japan
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Target Disease Prevalence
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. Reimbursement Framework
      • 9.4.2.5. Japan Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3. China
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Target Disease Prevalence
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Reimbursement Framework
      • 9.4.3.5. China Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Target Disease Prevalence
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. Reimbursement Framework
      • 9.4.4.5. India Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.5. Australia
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Target Disease Prevalence
      • 9.4.5.3. Regulatory Framework
      • 9.4.5.4. Reimbursement Framework
      • 9.4.5.5. Australia Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.6. South Korea
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Target Disease Prevalence
      • 9.4.6.3. Regulatory Framework
      • 9.4.6.4. Reimbursement Framework
      • 9.4.6.5. South Korea Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Target Disease Prevalence
      • 9.4.7.3. Regulatory Framework
      • 9.4.7.4. Reimbursement Framework
      • 9.4.7.5. Thailand Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Target Disease Prevalence
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Reimbursement Framework
      • 9.5.2.5. Brazil Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3. Argentina
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Target Disease Prevalence
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Reimbursement Framework
      • 9.5.3.5. Argentina Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Middle East & Africa
    • 9.6.1. Middle East & Africa Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Target Disease Prevalence
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Reimbursement Framework
      • 9.6.2.5. South Africa Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Target Disease Prevalence
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Reimbursement Framework
      • 9.6.3.5. Saudi Arabia Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Target Disease Prevalence
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. Reimbursement Framework
      • 9.6.4.5. UAE Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Target Disease Prevalence
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Reimbursement Framework
      • 9.6.5.5. Kuwait Peptide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis by Key Market Participants
  • 10.2. Company Categorization
  • 10.3. Participant Overview
  • 10.4. Financial Performance
  • 10.5. Product Bench Marking
  • 10.6. Company Market Share Analysis, 2025
  • 10.7. Company Profiles
    • 10.7.1. Eli Lilly and Company
      • 10.7.1.1. Participant's Overview
      • 10.7.1.2. Financial Performance
      • 10.7.1.3. Product Benchmarking
      • 10.7.1.4. Recent Developments/ Strategic Initiatives
    • 10.7.2. Pfizer Inc.
      • 10.7.2.1. Participant's Overview
      • 10.7.2.2. Financial Performance
      • 10.7.2.3. Product Benchmarking
      • 10.7.2.4. Recent Developments/ Strategic Initiatives
    • 10.7.3. Amgen Inc.
      • 10.7.3.1. Participant's Overview
      • 10.7.3.2. Financial Performance
      • 10.7.3.3. Product Benchmarking
      • 10.7.3.4. Recent Developments/ Strategic Initiatives
    • 10.7.4. Takeda Pharmaceutical Company Limited
      • 10.7.4.1. Participant's Overview
      • 10.7.4.2. Financial Performance
      • 10.7.4.3. Product Benchmarking
      • 10.7.4.4. Recent Developments/ Strategic Initiatives
    • 10.7.5. AstraZeneca
      • 10.7.5.1. Participant's Overview
      • 10.7.5.2. Financial Performance
      • 10.7.5.3. Product Benchmarking
      • 10.7.5.4. Recent Developments/ Strategic Initiatives
    • 10.7.6. Teva Pharmaceutical Industries Ltd.
      • 10.7.6.1. Participant's Overview
      • 10.7.6.2. Financial Performance
      • 10.7.6.3. Product Benchmarking
      • 10.7.6.4. Recent Developments/ Strategic Initiatives
    • 10.7.7. Sanofi
      • 10.7.7.1. Participant's Overview
      • 10.7.7.2. Financial Performance
      • 10.7.7.3. Product Benchmarking
      • 10.7.7.4. Recent Developments/ Strategic Initiatives
    • 10.7.8. F. Hoffmann-La Roche Ltd
      • 10.7.8.1. Participant's Overview
      • 10.7.8.2. Financial Performance
      • 10.7.8.3. Product Benchmarking
      • 10.7.8.4. Recent Developments/ Strategic Initiatives
    • 10.7.9. Novartis AG
      • 10.7.9.1. Participant's Overview
      • 10.7.9.2. Financial Performance
      • 10.7.9.3. Product Benchmarking
      • 10.7.9.4. Recent Developments/ Strategic Initiatives
    • 10.7.10. Novo Nordisk A/S
      • 10.7.10.1. Participant's Overview
      • 10.7.10.2. Financial Performance
      • 10.7.10.3. Product Benchmarking
      • 10.7.10.4. Recent Developments/ Strategic Initiatives
    • 10.7.11. GSK plc
      • 10.7.11.1. Participant's Overview
      • 10.7.11.2. Financial Performance
      • 10.7.11.3. Product Benchmarking
      • 10.7.11.4. Recent Developments/ Strategic Initiatives
    • 10.7.12. Ironwood Pharmaceuticals, Inc.
      • 10.7.12.1. Participant's Overview
      • 10.7.12.2. Financial Performance
      • 10.7.12.3. Product Benchmarking
      • 10.7.12.4. Recent Developments/ Strategic Initiatives
    • 10.7.13. Radius Health, Inc. (Subsidiary of Gurnet Point Capital and Patient Square Capital)
      • 10.7.13.1. Participant's Overview
      • 10.7.13.2. Financial Performance
      • 10.7.13.3. Product Benchmarking
      • 10.7.13.4. Recent Developments/ Strategic Initiatives
    • 10.7.14. Ipsen Pharma
      • 10.7.14.1. Participant's Overview
      • 10.7.14.2. Financial Performance
      • 10.7.14.3. Product Benchmarking
      • 10.7.14.4. Recent Developments/ Strategic Initiatives

Chapter 11. Conclusion

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America peptide therapeutics market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 4 North America peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 5 North America peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 6 North America peptide therapeutics market estimates and forecasts, by type of manufacturer, 2021 - 2033 (USD Million)
  • Table 7 North America peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 8 North America peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 9 U.S. peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 10 U.S. peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 11 U.S. peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 12 U.S. peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 13 U.S. peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 14 Canada peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 15 Canada peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 16 Canada peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 17 Canada peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 18 Canada peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 20 Mexico peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 21 Mexico peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 22 Mexico peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 23 Mexico peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 24 Europe peptide therapeutics market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 25 Europe peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 26 Europe peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 27 Europe peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 28 Europe peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 29 Europe peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 30 UK peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 31 UK peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 32 UK peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 33 UK peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 34 UK peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 35 Germany peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 36 Germany peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 37 Germany peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 38 Germany peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 39 Germany peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 40 France peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 41 France peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 42 France peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 43 France peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 44 France peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 45 Spain peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 46 Spain peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 47 Spain peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 48 Spain peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 49 Spain peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 50 Italy peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 51 Italy peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 52 Italy peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 53 Italy peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 54 Italy peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 55 Denmark peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 56 Denmark peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 57 Denmark peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 58 Denmark peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 59 Denmark peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 60 Sweden peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 61 Sweden peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 62 Sweden peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 63 Sweden peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 64 Sweden peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 65 Norway peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 66 Norway peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 67 Norway peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 68 Norway peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 69 Norway peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 70 Asia Pacific peptide therapeutics market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 71 Asia Pacific peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 72 Asia Pacific peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 73 Asia Pacific peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 74 Asia Pacific peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 75 Asia Pacific peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 76 Japan peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 77 Japan peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 78 Japan peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 79 Japan peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 80 Japan peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 81 China peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 82 China peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 83 China peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 84 China peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 85 China peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 86 India peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 87 India peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 88 India peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 89 India peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 90 India peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 91 South Korea peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 92 South Korea peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 93 South Korea peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 94 South Korea peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 95 South Korea peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 96 Australia peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 97 Australia peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 98 Australia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 99 Australia peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 100 Australia peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 101 Thailand peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 102 Thailand peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 103 Thailand peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 104 Thailand peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 105 Thailand peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 106 Latin America peptide therapeutics market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 107 Latin America peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 108 Latin America peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 109 Latin America peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 110 Latin America peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 111 Latin America peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 112 Brazil peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 113 Brazil peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 114 Brazil peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 115 Brazil peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 116 Brazil peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 117 Argentina peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 118 Argentina peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 119 Argentina peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 120 Argentina peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 121 Argentina peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 122 Middle East & Africa peptide therapeutics market estimates and forecasts, by country, 2021 - 2033 (USD Million)
  • Table 123 Middle East & Africa peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 124 Middle East & Africa peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 125 Middle East & Africa peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 126 Middle East & Africa peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 127 Middle East & Africa peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 128 South Africa peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 129 South Africa peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 130 South Africa peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 131 South Africa peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 132 South Africa peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 133 UAE peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 134 UAE peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 135 UAE peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 136 UAE peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 137 UAE peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 138 Saudi Arabia peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 139 Saudi Arabia peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 140 Saudi Arabia peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 141 Saudi Arabia peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 142 Saudi Arabia peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)
  • Table 143 Kuwait peptide therapeutics market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 144 Kuwait peptide therapeutics market estimates and forecasts, by application, 2021 - 2033 (USD Million)
  • Table 145 Kuwait peptide therapeutics market estimates and forecasts, by type of manufacturers, 2021 - 2033 (USD Million)
  • Table 146 Kuwait peptide therapeutics market estimates and forecasts, by route of administration, 2021 - 2033 (USD Million)
  • Table 147 Kuwait peptide therapeutics market estimates and forecasts, by synthesis technology, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Peptide therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application segment snapshot
  • Fig. 10 Type and type of manufacturers segment snapshot
  • Fig. 11 Route of administration and synthesis technology segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Pharmaceutical market (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 The most common cancers globally are listed in the table below
  • Fig. 16 Global number of new cases caused by top 11 cancer types in 2023 (in thousands)
  • Fig. 17 The figure below shows the phase of therapeutic peptides in clinical trials:
  • Fig. 18 Porter's five forces analysis
  • Fig. 19 PESTLE analysis
  • Fig. 20 Peptide therapeutics market: Type outlook and key takeaways
  • Fig. 21 Peptide therapeutics market: Type movement analysis
  • Fig. 22 Generic market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Innovative market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Peptide therapeutics market: Application outlook and key takeaways
  • Fig. 25 Peptide therapeutics market: Application movement analysis
  • Fig. 26 Cancer market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Metabolic disorders market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 Cardiovascular disorders market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Respiratory disorders market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Gastrointestinal disorders market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 31 Infectious diseases market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Pain market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Dermatological disorders market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Neurological disorders market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 35 Renal disorders market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 36 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 37 Peptide therapeutics market: Type of manufacturers outlook and key takeaways
  • Fig. 38 Peptide therapeutics market: Type of manufacturers movement analysis
  • Fig. 39 In-house market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 40 Outsourced market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 41 Peptide therapeutics market: Route of administration outlook and key takeaways
  • Fig. 42 Peptide therapeutics market: Route of administration movement analysis
  • Fig. 43 Parenteral route market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Oral route market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 45 Pulmonary market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Mucosal market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 47 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Peptide therapeutics market: Synthesis technology outlook and key takeaways
  • Fig. 49 Peptide therapeutics market: Synthesis technology movement analysis
  • Fig. 50 Solid Phase Peptide Synthesis (SPPS) market estimates and Forecast, 2021 - 2033 (USD Million)
  • Fig. 51 Recombinant DNA technology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 52 Hybrid technology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 Liquid-Phase Peptide Synthesis (LPPS) technology market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 54 Others market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 55 Peptide therapeutics market revenue, by region, 2025 & 2033 (USD Million)
  • Fig. 56 Regional marketplace: Key takeaways
  • Fig. 57 North America peptide therapeutics market estimates and forecasts, 2021 - 2033 ((USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Target disease prevalence
  • Fig. 60 U.S. peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Target disease prevalence
  • Fig. 63 Canada peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Mexico peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Target disease prevalence
  • Fig. 67 Europe peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Target disease prevalence
  • Fig. 70 UK peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Target disease prevalence
  • Fig. 73 Germany peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Target disease prevalence
  • Fig. 76 France peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Target disease prevalence
  • Fig. 79 Spain peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Target disease prevalence
  • Fig. 82 Italy peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Target disease prevalence
  • Fig. 85 Denmark peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Target disease prevalence
  • Fig. 88 Sweden peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Target disease prevalence
  • Fig. 91 Norway peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Rest of Europe peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 93 Asia Pacific peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Target disease prevalence
  • Fig. 96 Japan peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Target disease prevalence
  • Fig. 99 China peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Target disease prevalence
  • Fig. 102 India peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Target disease prevalence
  • Fig. 105 Australia peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Thailand peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 South Korea peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 110 Rest of Asia Pacific peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 111 Latin America peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 112 Key country dynamics
  • Fig. 113 Target disease prevalence
  • Fig. 114 Brazil peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 115 Key country dynamics
  • Fig. 116 Target disease prevalence
  • Fig. 117 Argentina peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 118 Rest of Latin America peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 119 Middle East & Africa peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 120 Key country dynamics
  • Fig. 121 Target disease prevalence
  • Fig. 122 South Africa peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 123 Key country dynamics
  • Fig. 124 Target disease prevalence
  • Fig. 125 Saudi Arabia peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 126 Key country dynamics
  • Fig. 127 Target disease prevalence
  • Fig. 128 UAE peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 129 Key country dynamics
  • Fig. 130 Target disease prevalence
  • Fig. 131 Kuwait peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 132 Rest of Middle East & Africa peptide therapeutics market estimates and forecasts, 2021 - 2033 (USD Million)